Spun out of University of Texas Southwestern Medical Center in Dallas, Onconano Medicine Inc is a biotech company developing a new class of products that exploit universal cancer and immune therapeutic targets to diagnose and treat cancer: nanotechnology-enabled fluorescent probes designed to assist cancer surgeons towards recognizing tumors while operating. This approach represents a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease. The firm's lead product, ONM-100, is an injectable imaging agent that targets the acidic pH within tumors enabling the surgeon better distinguish cancer cells from those that are healthy. Onconano is also developing an IV injectable nanoparticle platform known as Tumor Transistors, along with various cancer care technology.
